Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series E brings in $8.5mm for Ocular Therapeutix

Executive Summary

Ophthalmic drug/device developer Ocular Therapeutix Inc. has raised $8.5mm through what appears to be its Series E venture round. Baxter Ventures acquired a minority stake, and was joined by returning shareholder Ascension Health Ventures. Ocular will use the new money to continue developing its sustained-release drug candidates, including prostaglandin analogs for glaucoma and corticosteroids for post-operative inflammation and pain. The company will also use the funding to support the launch of its ReSure surgical sealant for clear corneal incisions following the implantation of lenses. The company closed its $9.8mm Series D extension at the end of 2012.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies